AlloSure Kidney helps detect injury earlier²˒³ and across rejection types.¹˒⁴
Catch rejection early, intervene sooner
Allosure is a robust predictor for all types of kidney rejection, including microvascular inflammation (MVI), even in DSA-negative and C4d-negative cases.¹˒⁴
Widely trusted across kidney transplant programs
Used by 160+ transplant centers, AlloSure is the most widely adopted dd-cfDNA test in transplant
Most published dd-cfDNA test
In transplant⁸
Largest international kidney transplant study
With paired biopsies to evaluate dd-cfDNA (n=2,771)⁴,⁷
60+ journal publications
Feature AlloSure⁸
Only test to detect both TCMR and AMR
That is validated in a real-world, long-term surveillance study²
AlloSure Plus: AI-derived insight through Epic Aura
Resources
Incorporating AlloSure into your workflow
How to Order AlloSure
Find the steps needed to place an order, with ordering options that fit your center.
Interpretation Guides
Access practical guidance for understanding and interpreting results.
Downloads
Webinars
Events
Connect with our team to learn more about AlloSure Kidney
Obrișcă B, Butiu M, Sibulesky L, et al. Combining donor-derived cell-free DNA and donor specific antibody testing as non-invasive biomarkers for rejection in kidney transplantation. Sci Rep. 2022;12(1):15061.
Bu L, Gupta G, Pai A, et al. Clinical outcomes from the Assessing Donor-derived cell-free DNA Monitoring Insights of kidney Allografts with Longitudinal surveillance (ADMIRAL) study. Kidney Int. 2022;101(4):793-803.
Bromberg JS, Brennan DC, Taber DJ, et al. Donor-derived cell-free DNA significantly improves rejection yield in kidney transplant biopsies. Am J Transplant. 2025;25(12):2529-2542.
Aubert O, Ursule-Dufait C, Brousse R, et al. Cell-free DNA for the detection of kidney allograft rejection. Nat Med. 2024;30(8):2320-2327.
Wojciechowski D, Alhamad T, Kumar D, et al. dd-cfDNA predicts long-term graft outcomes: Kidney Allograft Outcomes AlloSure Registry (KOAR) results: TH-PO1224. J Am Soc Nephrol. 2025;36(10S):10.1681/ASN.2025dtk3ypbg.
Pai A, Swan JT, Wojciechowski D, et al. Clinical rationale for a routine testing schedule using donor-derived cell-free DNA after kidney transplantation. Ann Transplant. 2021;26:e932249.
Oral WTC presentation by Dr. Romain Brousse on August 5, 2025 (assessing performance of AlloSure Plus without DSA); CareDx data on file.
Data on file. CareDx; 2025. 24. Melancon JK, Khalil A, Lerman MJ. Donor-derived cell free DNA: is it all the same? Kidney360. 2020;1(10):1118-1123.
Williams MD, Fei M, Schadde E, et al. Transplantation Direct 2022; 8:e1321. doi: 10.1097/TXD.0000000000001321.
Yoo A, Riedel A, Qian I, et al. Transplantation Direct 2023; 9:e1459. doi: 10.1097/TXD.0000000000001459